Loading...
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel, M Singh, S Strosberg, J Bubuteishvili-Pacaud, L Degtyarev, E Neary, M Carnaghi, C Tomasek, J Wolin, E Raderer, M
Pavel, M
Singh, S
Strosberg, J
Bubuteishvili-Pacaud, L
Degtyarev, E
Neary, M
Carnaghi, C
Tomasek, J
Wolin, E
Raderer, M
Citations
Altmetric:
Abstract
In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint.
Description
Date
2017-08-21
Publisher
Collections
Keywords
Type
Article
Citation
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2017 Lancet Oncol